Sugi Predict

Sugi Predict / Compounds / SCHEMBL1996550

SCHEMBL1996550

SCHEMBL1996550

CC(=O)c1ccc(C(F)(F)F)cc1C(F)(F)F

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 3/20 0.72
▸ ALDH1A1 P00352 3/20 0.50
▸ HPGD P15428 3/20 0.50
▸ HSD17B10 Q99714 3/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ USP2 O75604 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ FLT1 P17948 1/20 0.48
▸ FLT4 P35916 1/20 0.48
▸ KDR P35968 1/20 0.48
▸ CFTR P13569 1/20 0.47
▸ AVPR2 P30518 1/20 0.46
▸ GPR27 Q9NS67 1/20 0.46
▸ MAPT P10636 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ TRPV4 Q9HBA0 1/20 0.43
▸ POLQ O75417 3/20 0.42
▸ SORT1 Q99523 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30481870 1.00 CES2 (0.72) CES2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL2001145 0.85 CES2 (0.72) CES2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL31004884 0.85 CES2 (0.72) CES2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL424263 0.84 CES2 (0.78) CES2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL21852902 0.84 CES2 (0.55) CES2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL18243902 0.84 CES2 (0.66) CES2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL11805874 0.82 CES2 (0.75) CES2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL18291815 0.82 ALDH1A1 (0.56) CES2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL22407060 0.82 CES2 (0.50) CES2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL8491028 0.81 CES2 (0.62) CES2ALDH1A1HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 — — US claimed
US-12325702-B2 ATF6 inhibitors and uses thereof ALTOS LABS, INC. (US) 2025-06-10 — — US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
US-20240124434-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2024-04-18 — — US disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2021-07-22 — — US disclosed
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ALTOS LABS, INC. 2021-07-22 — — US disclosed
EP-3774782-A2 ATF6 INHIBITORS AND USES THEREOF Black Belt TX Ltd (GB) 2021-02-17 — — EP disclosed
US-10829485-B2 ATF6 inhibitors and uses thereof BLACK BELT TX LTD (GB) 2020-11-10 — — US disclosed
EP-1450901-A2 (1-PHENYL-2-HETEROARYL)ETHYL-GUANIDINE COMPOUNDS AS INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE Bristol-Myers Squibb Company (US) 2004-09-01 — — EP disclosed
EP-1432706-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 — — EP disclosed
US-20040039033-A1 (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase BRISTOL-MYERS SQUIBB COMPANY 2004-02-26 — — US disclosed
WO-2004014887-A1 PROCESS FOR PRODUCING TRIFLUOROMETHYL-SUBSTITUTED 2-ALKOXYACETOPHENONE DERIVATIVES CENTRAL GLASS COMPANY, LIMITED (JP) 2004-02-19 — — WO disclosed
WO-2003072566-A1 FUSED TRICYCLIC HETEROCYCLES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-09-04 — — WO disclosed
WO-2003050261-A2 (1-PHENYL-2-HETEROARYL)ETHYL-GUANIDINE COMPOUNDS AS INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-19 — — WO disclosed
WO-2003027085-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 — — WO disclosed
EP-0735142-B1 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICALS CO LTD (JP) 2001-10-24 — — EP disclosed
US-5717116-A TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) 1998-02-10 — — US disclosed
EP-0735142-A2 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) 1996-10-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124434-A1 ATF6 INHIBITORS AND USES THEREOF ATF4, XBP1, ATF1 CES2 2791/4885ALDH1A1 4447/4885HPGD 2636/4885
US-12325702-B2 ATF6 inhibitors and uses thereof ATF4, XBP1, ATF1 CES2 2791/4885ALDH1A1 4447/4885HPGD 2636/4885
US-10829485-B2 ATF6 inhibitors and uses thereof ATF4, XBP1, ATF1 CES2 2791/4885ALDH1A1 4447/4885HPGD 2636/4885
US-20210221803-A1 ATF6 INHIBITORS AND USES THEREOF ATF4, XBP1, ATF1 CES2 2791/4885ALDH1A1 4447/4885HPGD 2636/4885
US-20040039033-A1 (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase ATP5F1A, ATP5ME, ATP5F1D CES2 2404/4885ALDH1A1 422/4885HPGD 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.